- Home
- BLTE vs VNET Comparison
BLTE vs VNET Comparison
Compare BLTE & VNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLTE
- VNET
- Stock Information
- Founded
- BLTE 2018
- VNET 1999
- Country
- BLTE United States
- VNET China
- Employees
- BLTE N/A
- VNET N/A
- Industry
- BLTE Biotechnology: Pharmaceutical Preparations
- VNET Computer Software: Programming Data Processing
- Sector
- BLTE Health Care
- VNET Technology
- Exchange
- BLTE Nasdaq
- VNET Nasdaq
- Market Cap
- BLTE 2.1B
- VNET 2.4B
- IPO Year
- BLTE 2022
- VNET 2011
- Fundamental
- Price
- BLTE $66.70
- VNET $8.25
- Analyst Decision
- BLTE Strong Buy
- VNET Strong Buy
- Analyst Count
- BLTE 4
- VNET 3
- Target Price
- BLTE $96.67
- VNET $10.73
- AVG Volume (30 Days)
- BLTE 53.3K
- VNET 11.9M
- Earning Date
- BLTE 03-17-2025
- VNET 03-12-2025
- Dividend Yield
- BLTE N/A
- VNET N/A
- EPS Growth
- BLTE N/A
- VNET N/A
- EPS
- BLTE N/A
- VNET 0.02
- Revenue
- BLTE N/A
- VNET $1,131,518,816.00
- Revenue This Year
- BLTE N/A
- VNET $12.08
- Revenue Next Year
- BLTE N/A
- VNET $15.15
- P/E Ratio
- BLTE N/A
- VNET $87.59
- Revenue Growth
- BLTE N/A
- VNET 11.41
- 52 Week Low
- BLTE $31.01
- VNET $1.42
- 52 Week High
- BLTE $86.53
- VNET $16.13
- Technical
- Relative Strength Index (RSI)
- BLTE 58.99
- VNET 38.68
- Support Level
- BLTE $64.10
- VNET $8.23
- Resistance Level
- BLTE $67.40
- VNET $9.07
- Average True Range (ATR)
- BLTE 2.33
- VNET 0.74
- MACD
- BLTE -0.33
- VNET -0.37
- Stochastic Oscillator
- BLTE 37.74
- VNET 9.09
About BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About VNET VNET Group Inc.
VNET started as AsiaCloud in 1999 and moved to the data center business with its first self-developed data center opening in 2010. The firm listed (as 21Vianet) on the Nasdaq in April 2011, subsequently changing its name to VNET Group in 2021. It originally focused on providing data center services such as colocation and cloud services to retail clients in China, but added hyperscale customers in 2019 and now counts large Chinese hyperscalers such as Alibaba Cloud, Tencent Cloud, and Huawei Cloud as customers. At the end of June 2024, it had 48,516 self-built retail cabinets with the majority in Beijing, Shanghai, and the Greater Bay area. It also had 358 MW of wholesale capacity in service with a further 297 MW under construction and a further 489 MW held for future development.